US HB938 | 2019-2020 | 116th Congress
Status
Spectrum: Moderate Partisan Bill (Democrat 13-4)
Status: Introduced on January 31 2019 - 25% progression, died in chamber
Action: 2019-05-02 - Placed on the Union Calendar, Calendar No. 24.
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on January 31 2019 - 25% progression, died in chamber
Action: 2019-05-02 - Placed on the Union Calendar, Calendar No. 24.
Text: Latest bill text (Introduced) [PDF]
Summary
To amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes.
Title
BLOCKING Act of 2019 Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019
Sponsors
| Rep. Kurt Schrader [D-OR] | Rep. Earl Carter [R-GA] | Rep. Angela Craig [D-MN] | Rep. Debbie Dingell [D-MI] |
| Rep. Raul Ruiz [D-CA] | Rep. Frank Pallone [D-NJ] | Rep. Anna Eshoo [D-CA] | Rep. Joseph Kennedy [D-MA] |
| Rep. Doris Matsui [D-CA] | Rep. Bobby Rush [D-IL] | Rep. Jeff Van Drew [R-NJ] | Rep. Yvette Clarke [D-NY] |
| Rep. Greg Walden [R-OR] | Rep. Janice Schakowsky [D-IL] | Rep. Ben McAdams [D-UT] | Rep. Debbie Mucarsel-Powell [D-FL] |
| Rep. Mark Meadows [R-NC] |
History
| Date | Chamber | Action |
|---|---|---|
| 2019-05-02 | House | Placed on the Union Calendar, Calendar No. 24. |
| 2019-05-02 | House | Reported by the Committee on Energy and Commerce. H. Rept. 116-46. |
| 2019-04-03 | House | Ordered to be Reported by Voice Vote. |
| 2019-04-03 | House | Committee Consideration and Mark-up Session Held. |
| 2019-03-27 | House | Forwarded by Subcommittee to Full Committee by Voice Vote . |
| 2019-03-27 | House | Subcommittee Consideration and Mark-up Session Held. |
| 2019-02-02 | House | Referred to the Subcommittee on Health. |
| 2019-01-31 | House | Referred to the House Committee on Energy and Commerce. |
| 2019-01-31 | House | Introduced in House |
Same As/Similar To
HB987 (Related) 2019-05-20 - Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
HB2700 (Related) 2019-06-26 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
HB19 (Related) 2019-12-19 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
HB2700 (Related) 2019-06-26 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
HB19 (Related) 2019-12-19 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Subjects
Competition and antitrust
Drug safety, medical device, and laboratory regulation
Health
Health care costs and insurance
Health care coverage and access
Licensing and registrations
Marketing and advertising
Prescription drugs
Drug safety, medical device, and laboratory regulation
Health
Health care costs and insurance
Health care coverage and access
Licensing and registrations
Marketing and advertising
Prescription drugs
